- Home
- TONX vs KPTI Comparison
TONX vs KPTI Comparison
Compare TONX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TONX | KPTI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.5M | 172.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | TONX | KPTI |
|---|---|---|
| Price | $2.66 | $5.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 361.6K | ★ 659.3K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | $526.82 | N/A |
| Revenue Next Year | $45.45 | $46.62 |
| P/E Ratio | $0.26 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.75 | $3.51 |
| 52 Week High | $8.23 | $10.99 |
Technical Indicators
Market Signals| Indicator | TONX | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 26.97 |
| Support Level | $1.80 | $3.95 |
| Resistance Level | $3.61 | $6.96 |
| Average True Range (ATR) | 0.29 | 0.88 |
| MACD | -0.02 | -0.36 |
| Stochastic Oscillator | 23.66 | 6.20 |
Price Performance
Historical ComparisonAbout TONX TON Strategy Company
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).